Brands, Medical Use, Clinical Data
Brands / Synonyms
Acamprosate 6473; Acamprosate 6473 [Inn]; Acamprosato [Inn-Spanish]; Acamprosatum [Inn-Latin]; Campral; N-Acetylhomotaurine
For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence. Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.
Mechanism of Action
The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. in vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance.
Biotrnasformation / Drug Metabolism
CAMPRAL is contraindicated in patients who previously have exhibited hypersensitivity to
acamprosate calcium or any of its components.
CAMPRAL is contraindicated in patients with severe renal impairment (creatinine clearance
The concomitant intake of alcohol and CAMPRAL does not affect the pharmacokinetics of either
alcohol or acamprosate.
Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the
pharmacokinetics of acamprosate. Co-administration of naltrexone with CAMPRAL produced a 25% increase in AUC
and a 33% increase in the Cmax of acamprosate. No adjustment of dosage is recommended in such
The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected
following co-administration with CAMPRAL.
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with
CAMPRAL concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid
analgesics was similar to that of subjects taking placebo with these concomitant medications. Patients taking
CAMPRAL concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared
with patients taking either medication alone.